Personalized Therapies for Atrial Fibrillation. A Translational Approach
Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans with a cost exceeding 1% of the EU health care system budget (13.5 billion annually). New treatment strategies and the progress...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TARGET
Health virtual twins for the personalised management of stro...
7M€
Cerrado
PID2020-114291RB-I00
GEMELOS VIRTUALES INTELLIGENTES DEL CORAZON PARA ESTRATIFICA...
151K€
Cerrado
GUIDE-AF
Personalized Phenotype of Atrial Fibrillation for Accurate T...
204K€
Cerrado
MAESTRIA
Machine Learning Artificial Intelligence Early Detection Str...
15M€
Cerrado
PID2019-104356RB-C43
MODELO COMPUTACIONAL MECANO-ELECTRICO DE CORAZON HUMANO PARA...
138K€
Cerrado
CompBioMed2
A Centre of Excellence in Computational Biomedicine
8M€
Cerrado
Información proyecto PersonalizeAF
Duración del proyecto: 54 meses
Fecha Inicio: 2019-09-11
Fecha Fin: 2024-03-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans with a cost exceeding 1% of the EU health care system budget (13.5 billion annually). New treatment strategies and the progress achieved in research on AF mechanisms and substrate evaluation methods to date have not been commensurate with an equivalent development of the knowledge and technologies required to individually characterize each patient in search of the most efficient therapy.
PersonalizeAF addresses this challenge by delivering an innovative multinational, multi-sectorial, and multidisciplinary research and training programme in new technologies and novel strategies for individualized characterization of AF substrate to and increase treatments’ efficiency.
From the research point of view, PersonalizeAF will integrate data and knowledge from in-vitro, in silico, ex vivo and in vivo animal and human models to: 1) generate an individual description of the state of the atrial muscle identifying the disease mechanisms and characteristics; 2) understanding the potential effect that different therapies have on different atrial substrates; and 3) combining this information to generate a specific profile of the patient and the best therapy for each patient.
With this purpose, PersonalizeAF partnership aggregates relevant scientific staff from the academic and clinical world with highly specialised biomedical companies which will be involved in a high-level personalised training programme that will train a new generation of highly skilled professionals and guarantee ESRs and future PhD students outstanding Career Opportunities in the biomedical engineering, cardiology services and medical devices sectors. PersonalizeAF will disseminate results to a wide spectrum of stakeholders, create awareness in the general public about atrial fibrillation and encourage vocational careers among young students.